Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Show more

Location: Level 10, Kuala Lumpur, 592000, Malaysia | Website: https://www.cyclacel.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

17.21M

52 Wk Range

$3.08 - $597.60

Previous Close

$7.68

Open

$7.53

Volume

30,970

Day Range

$7.26 - $7.59

Enterprise Value

12.78M

Cash

4.275M

Avg Qtr Burn

-2.182M

Insider Ownership

75.19%

Institutional Own.

0.99%

Qtr Updated

06/30/25